- Home
- MNMD vs SDHC Comparison
MNMD vs SDHC Comparison
Compare MNMD & SDHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- SDHC
- Stock Information
- Founded
- MNMD 2019
- SDHC 2008
- Country
- MNMD United States
- SDHC United States
- Employees
- MNMD N/A
- SDHC N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- SDHC
- Sector
- MNMD Health Care
- SDHC
- Exchange
- MNMD Nasdaq
- SDHC Nasdaq
- Market Cap
- MNMD 960.2M
- SDHC 794.4M
- IPO Year
- MNMD N/A
- SDHC 2024
- Fundamental
- Price
- MNMD $13.39
- SDHC $17.71
- Analyst Decision
- MNMD Strong Buy
- SDHC Hold
- Analyst Count
- MNMD 7
- SDHC 4
- Target Price
- MNMD $26.71
- SDHC $17.38
- AVG Volume (30 Days)
- MNMD 1.8M
- SDHC 106.0K
- Earning Date
- MNMD 10-31-2025
- SDHC 11-05-2025
- Dividend Yield
- MNMD N/A
- SDHC N/A
- EPS Growth
- MNMD N/A
- SDHC N/A
- EPS
- MNMD N/A
- SDHC N/A
- Revenue
- MNMD N/A
- SDHC $1,013,967,000.00
- Revenue This Year
- MNMD N/A
- SDHC $1.27
- Revenue Next Year
- MNMD N/A
- SDHC $8.41
- P/E Ratio
- MNMD N/A
- SDHC N/A
- Revenue Growth
- MNMD N/A
- SDHC 22.89
- 52 Week Low
- MNMD $4.70
- SDHC $15.00
- 52 Week High
- MNMD $14.30
- SDHC $37.90
- Technical
- Relative Strength Index (RSI)
- MNMD 60.21
- SDHC 50.35
- Support Level
- MNMD $12.41
- SDHC $15.41
- Resistance Level
- MNMD $13.74
- SDHC $18.57
- Average True Range (ATR)
- MNMD 0.84
- SDHC 0.71
- MACD
- MNMD -0.06
- SDHC 0.23
- Stochastic Oscillator
- MNMD 52.55
- SDHC 66.67
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.